Serological CTX-II does not measure the same as urinary CTX-II

Area of Science:

• Biochemistry
• Biomarkers
• Osteoarthritis Research

Background:

• Type II collagen is crucial for articular cartilage integrity.
• Urinary cross-linked C-terminal telopeptide of type II collagen (uCTX-II) is a validated osteoarthritis biomarker.
• Developing a serum assay (sCTX-II) for collagen degradation is of significant interest.

Purpose of the Study:

• To develop a serological immunoassay for CTX-II (sCTX-II).
• To evaluate the biological relevance of sCTX-II in cartilage explants.
• To assess sCTX-II and uCTX-II levels in an osteoarthritis cohort and their clinical correlations.

Main Methods:

• Validated sCTX-II in bovine cartilage explants stimulated with Oncostatin M and TNF-alpha.
• Assayed serum sCTX-II and urine uCTX-II in an osteoarthritis patient cohort.
• Utilized Spearman's correlation to analyze biomarker relationships and clinical associations.

Main Results:

• sCTX-II levels increased in explant supernatants, suppressed by GM6001, indicating MMP-mediated release.
• Serum sCTX-II did not correlate with urinary uCTX-II.
• Neither serum sCTX-II nor urinary uCTX-II showed clinical relevance in the cross-sectional cohort, though uCTX-II correlated with age and gender.

Conclusions:

• The sCTX-II assay reflects MMP-mediated type II collagen degradation in cartilage explants.
• Serum sCTX-II and urine uCTX-II exhibit different patterns, suggesting distinct biological origins or processing.
• Further research is needed to establish the clinical utility of serum CTX-II in osteoarthritis.